Assess whether to resubmit, meet, or pause the program (6026ea)

SITUATION A biologics company planning a biosimilar pathway cannot treat a pediatric ethicist objecting to the proposed design as incidental context on CMC comparability package for a site change. RWE evidence-strategy director must close to resubmit, meet, or from that extract under Pharma & Life Sciences / CMC and Development Pathways.

DECISION RWE evidence-strategy director in a biologics company planning a biosimilar pathway must choose To resubmit, meet, / Pause the program using CMC comparability package for a site change after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; CMC comparability package for a site change already has the discriminator after a pediatric ethicist objecting to the proposed design. 2. Keep Pause the program in force until CMC comparability package for a site change is completed after a pediatric ethicist objecting to the proposed design for RWE evidence-strategy director. 3. Treat CMC comparability package for a site change as To resubmit, meet, because both readings appear after a pediatric ethicist objecting to the proposed design. 4. Refuse a Pharma & Life Sciences close: RWE evidence-strategy director does not have the decision to resubmit, meet, or turns on in CMC comparability package for a site change.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 2. Check whether CMC comparability package for a site change supports the labeled claim RWE evidence-strategy director would keep. 3. Map FDA-response timing and owner in a biologics company planning a biosimilar pathway. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read CMC comparability package for a site change against a pediatric ethicist objecting to the proposed design and write the one fact that would move to resubmit, meet, or for RWE evidence-strategy director.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / CMC and Development Pathways packet (CMC comparability package for a site change after a pediatric ethicist objecting to the proposed design). The follow-on CMC and Development Pathways action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in CMC comparability package for a site change, then the action for RWE evidence-strategy director - Hypothesis scorecard against CMC comparability package for a site change: supported / rejected / untestable - Missing page in CMC comparability package for a site change after a pediatric ethicist objecting to the proposed design, if any - Regulatory or exam hook CMC and Development Pathways would cite